| pubmed-article:18049024 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18049024 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18049024 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:18049024 | lifeskim:mentions | umls-concept:C0022658 | lld:lifeskim |
| pubmed-article:18049024 | lifeskim:mentions | umls-concept:C0003015 | lld:lifeskim |
| pubmed-article:18049024 | lifeskim:mentions | umls-concept:C0126174 | lld:lifeskim |
| pubmed-article:18049024 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:18049024 | lifeskim:mentions | umls-concept:C1883712 | lld:lifeskim |
| pubmed-article:18049024 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:18049024 | pubmed:dateCreated | 2007-11-30 | lld:pubmed |
| pubmed-article:18049024 | pubmed:abstractText | Angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) are frequently used for the treatment for glomerulonephritis and diabetic nephropathy because of their albuminuria- or proteinuria-reducing effects. To many patients who are nonresponsive to monotherapy with these agents, combination therapy appears to be a good treatment option. In the present study, we examined the effects of the addition of an ARB (losartan) followed by titration upon addition and at 3 and 6 months (n=14) and the addition of an ACE-I followed by titration upon addition and at 3 and 6 months (n=20) to the drug regimen treatment protocol in type 2 diabetic patients with nephropathy for whom more than 3-month administration of an ACE-I or the combination of an ACE-I plus a conventional antihypertensive was ineffective to achieve a blood pressure (BP) of 130/80 mmHg and to reduce urinary albumin to <30 mg/day. During the 12-month treatment, addition of losartan or addition of an ACE-I to the treatment protocol reduced systolic blood pressure (SBP) by 10% and 12%, diastolic blood pressure (DBP) by 7% and 4%, and urinary albumin excretion by 38% and 20% of the baseline value, respectively. However, the effects on both BP and urinary albumin were not significantly different between the two therapies. In conclusion, addition of losartan or an ACE-I to an ongoing treatment with an ACE-I, or addition of an ACE-I to ongoing treatment with a conventional antihypertensive were equally effective at reducing the urinary albumin excretion and BP, and provided renal protection in patients with type-2 diabetic nephropathy. | lld:pubmed |
| pubmed-article:18049024 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18049024 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18049024 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18049024 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18049024 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18049024 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18049024 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18049024 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18049024 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18049024 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18049024 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18049024 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18049024 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:18049024 | pubmed:issn | 0916-9636 | lld:pubmed |
| pubmed-article:18049024 | pubmed:author | pubmed-author:MinatoguchiSh... | lld:pubmed |
| pubmed-article:18049024 | pubmed:author | pubmed-author:FujiwaraHisay... | lld:pubmed |
| pubmed-article:18049024 | pubmed:author | pubmed-author:TakatsuHisato... | lld:pubmed |
| pubmed-article:18049024 | pubmed:author | pubmed-author:TanakaTsutomu... | lld:pubmed |
| pubmed-article:18049024 | pubmed:author | pubmed-author:TsukamotoTats... | lld:pubmed |
| pubmed-article:18049024 | pubmed:author | pubmed-author:MurataIchijir... | lld:pubmed |
| pubmed-article:18049024 | pubmed:author | pubmed-author:MinagawaTaroT | lld:pubmed |
| pubmed-article:18049024 | pubmed:author | pubmed-author:OhashiHiroshi... | lld:pubmed |
| pubmed-article:18049024 | pubmed:author | pubmed-author:AbeHirohikoH | lld:pubmed |
| pubmed-article:18049024 | pubmed:author | pubmed-author:NaganoToshihi... | lld:pubmed |
| pubmed-article:18049024 | pubmed:author | pubmed-author:KakamiMasaoM | lld:pubmed |
| pubmed-article:18049024 | pubmed:author | pubmed-author:HieiKunihikoK | lld:pubmed |
| pubmed-article:18049024 | pubmed:author | pubmed-author:OkumaToshioT | lld:pubmed |
| pubmed-article:18049024 | pubmed:author | pubmed-author:YokoyamaHitom... | lld:pubmed |
| pubmed-article:18049024 | pubmed:author | pubmed-author:TakayaTadatak... | lld:pubmed |
| pubmed-article:18049024 | pubmed:author | pubmed-author:OsumiYukioY | lld:pubmed |
| pubmed-article:18049024 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18049024 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:18049024 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18049024 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18049024 | pubmed:pagination | 929-35 | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:meshHeading | pubmed-meshheading:18049024... | lld:pubmed |
| pubmed-article:18049024 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:18049024 | pubmed:articleTitle | Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy. | lld:pubmed |
| pubmed-article:18049024 | pubmed:affiliation | Second Department of Internal Medicine, Gifu University School of Medicine, Japan. | lld:pubmed |
| pubmed-article:18049024 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18049024 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:18049024 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18049024 | lld:pubmed |
